Antibody complexes and methods for immunolabeling

• US 8,323,903 B2
• Filed: 04/05/2002
• Issued: 12/04/2012
• Est. Priority Date: 10/12/2001
• Status: Expired due to Term

• Current Assignee: Life Technologies Corporation (Thermo Fisher Scientific Incorporated)
• Original Assignee: Life Technologies Corporation (Thermo Fisher Scientific Incorporated)
• Inventors: Archer, Robert A., Beechem, Joseph M., Hagen, David C., Haugland, Richard P., Haugland, Rosaria P.
• Primary Examiner(s): Cheu, Jacob
• Application Number:
  US10/118,204
• Publication Number:
  US 20030073149A1
• Time in Patent Office: 3,896 Days
• Field of Search: 435/5, 435/6, 435/9.1, 435/7.9, 435/91.2, 435/7.1, 436/536, 436/537, 436/540, 436/91, 436/814
• US Class Current: 435/7.1
• CPC Class Codes: B82Y 10/00 Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
• CPC Class Codes: B82Y 30/00 Nanotechnology for materials or surface science, e.g. nanocomposites
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: G01N 33/53 Immunoassay; Biospecific binding assay; Materials therefor
• CPC Class Codes: G01N 33/58 involving labelled substances G01N33/53 takes precedence
• CPC Class Codes: G01N 33/6857 Antibody fragments

Abstract

The present invention provides novel immunolabeling complexes and certain components of such complexes, as well as methods of preparing and using such complexes, and kits for use in preparing labeling proteins and for immunolabeling. The pre-formed immunolabeling complexes of the invention comprise both a target-binding antibody and a labeling protein that contains covalently attached labels, where the labeling protein binds selectively and with high affinity to a selected region of the target-binding antibody. Novel labeling proteins of the invention include non-antibody peptides and proteins, such as a complex of protein G and a labeled albumin, and monovalent antibody fragments, such as labeled Fab fragments of an anti-Fc antibody. In methods of the invention, the preformed immunolabeling complexes are added to the sample alone or in combination, for purposes of labeling and optionally detecting the target of interest.

Claims

1. A method for determining the presence of a desired target in a biological sample, said method comprising:

a) combining in a reaction vessel, at least one target-binding antibody comprising an Fc region with a labeling protein to form a labeling mixture, wherein the target-binding antibody is capable of binding to the target, and in the presence of the target, binds to it, wherein the target-binding antibody is non-covalently bound to the labeling protein, wherein the labeling protein comprises a monovalent anti-Fc antibody fragment comprising an Fc binding region that non-covalently binds to the Fc region on the target-binding antibody, wherein the labeling protein is independently covalently linked to one or more labels at a region other than the Fc binding region, wherein the one or more labels may be the same or different;

b) combining in the reaction vessel, the labeling mixture with a capture component to form a immunolabeling complex, wherein the capture component is capable of binding to labeling protein that did not bind to the target-binding antibody, and when unbound labeling protein is present, binds to the unbound labeling protein;

c) removing the immunolabeling complex from the reaction vessel;

d) combining the immunolabeling complex with the sample; and

e) detecting the presence or absence of the label whereby the presence or absence of said target is determined.

2. The method according to claim 1, wherein the labeling mixture contains two or more distinct target-binding antibodies non-covalently bound by labeling proteins, wherein one of the target-binding antibodies is non-covalently bound by a first labeling protein and the other target-binding antibody is non-covalently bound by a second labeling protein.

3. The method according to claim 1, wherein the target-binding antibody has two or more different labeling proteins non-covalently bound to the antibody and at least one labeling protein is detectably distinct from other labeling proteins.

4. The method according to claim 1, wherein the anti-Fc antibody fragment is derived from a monoclonal antibody or polyclonal antibody.

5. The method according to claim 4, wherein the polyclonal antibody is a rabbit or a goat polyclonal antibody.

6. The method according to claim 4, wherein the monoclonal antibody is classified as mouse IgM, IgG1, IgG2a, IgG2b, or IgG3 antibody, or an equivalent thereof.

7. The method according to claim 1, wherein the label is selected from the group consisting of a fluorescent dye, a phosphorescent dye, a tandem dye, a particle, an electron transfer agent, biotin, a hapten, an enzyme and a radioisotope.

8. The method according to claim 7, wherein the fluorescent dye is selected from the group consisting of a xanthene, a cyanine, a coumarin and a phycobiliprotein.

9. The method according to claim 7, wherein the tandem dye is selected from the group consisting of cyanine-phycobiliprotein and xanthene-phycobiliprotein.

10. The method according to claim 1, wherein the biological sample comprises eukaryotic or prokaryotic cells, cellular extract, subcellular component, proteins, peptides, tissue culture, tissue, a bodily fluid, or a portion or combination thereof.

11. The method according to claim 10, wherein the sample is immobilized on a surface.

12. The method according to claim 10, wherein the sample is in a gel or on a blot or in an array.

13. The method according to claim 1, wherein the amount of target-binding antibody is about 5 micrograms to about 0.001 micrograms.

14. The method according to claim 1, wherein the capture component is an antibody or an antibody fragment, and is optionally attached to a microsphere or to agarose.

15. The method according to claim 14, wherein the labeling mixture contains at least one target-binding antibody non-covalently bound to a labeling protein and

i) the labeling protein is a fragment of a rabbit or goat polyclonal antibody or of a mouse antibody,

ii) the labeling protein is an anti-Fc antibody fragment that is a monovalent Fab or Fab′

fragment, wherein the labeling protein is covalently labeled with one or more labels that are selected from the group consisting of a xanthene dye, a cyanine dye, a coumarin, a phycobiliprotein dye, cyanine-phycobiliprotein tandem dye, and xanthene-phycobiliprotein tandem dye, which labels are optionally the same or different; and

the capture component is an antibody or an antibody fragment, which is optionally attached to a microsphere or to agarose.

29. A method according to claim 1, further comprising stabilizing binding of the target-binding antibody to said labeling protein.

30. The method according to claim 7, wherein the enzyme is selected from the group consisting of peroxidase, phosphatase, glycosidase, and luciferases.

31. The method according to claim 30, wherein the method further comprises adding an enzymatic substrate selected from the group consisting of a chromogenic, fluorogenic and chemiluminescent substrate.

16. A method for determining the presence of a first and second desired targets in a biological sample, said method comprising:

a) combining in a first reaction vessel, a first target-binding antibody comprising an Fc region with a first labeling protein to form a first labeling mixture, wherein the first-target binding antibody is capable of binding to the first target, and in the presence of the first target, binds to it, wherein the first target-binding antibody is non-covalently bound to a first labeling protein, and wherein the first labeling protein comprises a monovalent anti-Fc antibody fragment comprising an Fc binding region that non-covalently binds to the Fc region of the first target-binding antibody;

b) combining in a second reaction vessel, a second target-binding antibody comprising an Fc region with a second labeling protein to form a second labeling mixture, wherein the second targeting-binding antibody is capable of binding to the second target, and in the presence of the second target, binds to it, wherein the second target-binding antibody is non-covalently bound to the second labeling protein, and wherein the second labeling protein comprises a monovalent anti-Fc antibody-fragment comprising an Fc binding region that non-covalently binds to the Fc region of the second target-binding antibody;

c) combining in the first reaction vessel, the first labeling mixture with a first capture component to form a first immunolabeling complex, wherein the first capture component is capable of binding to the first labeling protein that did not bind to the first target-binding antibody, and when unbound first labeling protein is present, binds to the unbound first labeling protein;

d) combining in the second reaction vessel, the second labeling mixture with a second capture component to form a second immunolabeling complex, wherein the second capture component is capable of binding to the second labeling protein that did not bind to the second target-binding antibody, and when unbound second labeling protein is present, binds to the unbound second labeling protein;

e) removing the first immunolabeling complex from the first reaction vessel;

f) removing the second immunolabeling complex from the second reaction vessel;

g) combining the first and second immunolabeling complexes with the sample; and

h) detecting the presence or absence of said labels whereby the presence or absence of said target is determined;

wherein the monovalent anti-Fc antibody fragments are detectably distinct, and wherein the labeling proteins are covalently linked to one or more labels at a region other than the Fc binding region.

17. The method according to claim 16, wherein the first and second antibody fragments are derived from a monoclonal antibody or polyclonal antibody.

18. The method according to claim 17, wherein the polyclonal antibody is a rabbit or a goat polyclonal antibody.

19. The method according to claim 17, wherein the monoclonal antibody is classified as mouse IgM, IgG1, IgG2a, IgG2b, or IgG3 antibody, or an equivalent thereof.

20. The method according to claim 16, wherein the labels are selected from the group consisting of a fluorescent dye, a phosphorescent dye, a tandem dye, a particle, an electron transfer agent, biotin, a hapten, an enzyme and a radioisotope.

21. The method according to claim 20, wherein the fluorescent dye is selected from the group consisting of a xanthene dye, a cyanine dye, a coumarin dye, and a phycobiliprotein dye.

22. The method according to claim 20, wherein the tandem dye is selected from the group consisting of cyanine-phycobiliprotein and xanthene-phycobiliprotein.

23. The method according to claim 16, wherein the biological sample comprises eukaryotic or prokaryotic cells, cellular extract, subcellular component, tissue culture, tissue, a bodily fluid, or a portion or combination thereof.

24. The method according to claim 23, wherein the amount of target-binding antibody is about 5 micrograms to about 0.001 micrograms.

25. The method of claim 16, wherein the sample is immobilized on a solid surface.

26. The method of claim 16, wherein the sample is in a gel, or on a blot or in an array.

27. The method according to claim 16, wherein the capture component is an antibody or an antibody fragment, and is optionally attached to a microsphere or to agarose.

28. The method according to claim 16, wherein the labeling mixture contains at least two target-binding antibodies each bound by at least one labeling protein;

and

a) the first and second labeling proteins are independently a fragment of a rabbit or goat polyclonal antibody or a mouse antibody,

b) the first and second labeling proteins are an anti-Fc antibody fragment that is a monovalent Fab or Fab′

fragment, wherein the first and second labeling proteins are covalently labeled with one or more labels that are independently selected from the group consisting of a xanthene dye, a cyanine dye, a coumarin, a phycobiliprotein dye, a cyanine-phycobiliprotein tandem dye, and xanthene-phycobiliprotein tandem dye, which labels are optionally the same or different; and

the capture component is an antibody or an antibody fragment, which is optionally attached to a microsphere or to agarose.

32. The method according to claim 20, wherein the enzyme is selected from the group consisting of peroxidase, phosphatase, glycosidase, and luciferases.

33. The method according to claim 32, wherein the method further comprises adding an enzymatic substrate selected from the group consisting of a chromogenic, fluorogenic and chemiluminescent substrate.